Alembic Pharmaceuticals has secured a significant approval from the US health regulator. The company's generic version of Carbidopa, Levodopa, and Entacapone tablets, used for Parkinson's disease, has been cleared by the USFDA. This development marks a crucial step for Alembic in the US market.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qLcCkGV
via IFTTT
No comments:
Post a Comment